Table 4 Subgroup analysis of the effect of drug switching strategies on the occurrence of the primary efficacy and safety endpoints.
Primary efficacy endpoint | All-cause mortality | AMI | Stroke | Ischemic Stroke | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
Adjusted HR (95%CI) | p-value | Adjusted HR (95%CI) | p-value | Adjusted HR (95%CI) | p-value | Adjusted HR (95%CI) | p-value | Adjusted HR (95%CI) | p-value | |
Clopidogrel without switching | 1 | 1 | 1 | 1 | ||||||
Ticagrelor without switching | 0.96 (0.71–1.29) | 0.770 | 0.71 (0.45–1.12) | 0.145 | 1.36 (0.90–2.07) | 0.146 | 0.41 (0.17–0.98) | 0.044 | 0.38 (0.15–0.97) | 0.043 |
From none/ticagrelor switching to clopidogrel | 1.68 (1.10–2.57) | 0.017 | 0.92 (0.45–1.89) | 0.817 | 2.62 (1.53–4.48) | 0.000 | 0.57 (0.13–2.49) | 0.453 | 0.68 (0.15–3.00) | 0.609 |
From none/clopidogrel switching to ticagrelor | 1.23 (0.84–1.80) | 0.283 | 1.00 (0.56–1.76) | 0.989 | 2.02 (1.24–3.28) | 0.005 | 0.43 (0.12–1.46) | 0.176 | 0.47 (0.14–1.63) | 0.233 |
Primary safety endpoint | Major GI bleeding | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Adjusted HR (95%CI) | p-value | Adjusted HR (95%CI) | p-value | |||||||
Clopidogrel without switching | 1 | 1 | ||||||||
Ticagrelor without switching | 0.57 (0.25–1.34) | 0.197 | 0.52 (0.21–1.28) | 0.153 | ||||||
From none/ticagrelor switching to clopidogrel | 0.90 (0.25–3.18) | 0.865 | 0.61 (0.13–2.78) | 0.520 | ||||||
From none/clopidogrel switching to ticagrelor | 0.86 (0.31–2.39) | 0.770 | 0.94 (0.33–2.66) | 0.909 | ||||||
